However, the lack of association between circulating TF+ MVs or MVs-TF activity and VTE in small cell lung, stomach, or colorectal cancer, and in multiple myeloma patients were found [254,255,256], limits the feasibility of TF-MVs as predictive factors of VTE risk in cancer patients. This evidence concerns the gene TF and AL amyloidosis.